A Phase 2 Study Evaluating the Efficacy and Safety of ALXN2050, a Complement Factor D inhibitor, in Patients With IgA Nephropathy (IgAN) or Proliferative Lupus Nephritis (LN)
ALXN-2050
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: A Phase 2 Study Evaluating the Efficacy and Safety of ALXN2050, a Complement Factor D inhibitor, in Patients With IgA Nephropathy (IgAN) or Proliferative Lupus Nephritis (LN) ### Output: ALXN-2050